MedGraph - Topaaz

MedGraph - Topaaz™ is an AI-automated drug discovery platform developed by Medvolt.ai, designed to revolutionize the way researchers design and optimize therapeutic candidates. By integrating de novo molecular design, generative AI, multiparameter optimization, and advanced virtual screening into a single end-to-end pipeline, the platform empowers pharmaceutical and biotech researchers to deliver precise, scalable, and efficient solutions across the full drug discovery lifecycle.

The platform is built for research teams seeking to dramatically compress drug discovery timelines — reducing the process from years to weeks — while maintaining a reported 99% accuracy rate in generating novel molecules with desired pharmacological properties. MedGraph - Topaaz™ supports workflows from initial target selection through to preclinical candidate optimization, making it suitable for both early-stage discovery and lead refinement programs.

Core Features

• De Novo Design: Build novel compounds from scratch using Medvolt's extensive fragment library, with AI-accelerated screening to rapidly identify high-potential candidates for specific therapeutic targets.
• Generative AI: Deep neural networks use top-ranked fragments as seeds to probabilistically generate diverse molecules, enabling the creation of vast active compound libraries in record time.
• AI-Driven Optimization: Reinforcement learning models optimize compounds for safety, efficacy, and other pharmacological properties, with automated candidate refinement that modifies and evolves molecular structures to improve the likelihood of clinical success.
• Virtual Screening: Molecular docking capabilities predict drug-target interactions and binding mechanisms, while drug-likeness prediction assesses ADME, physicochemical, and toxicity properties to support lead selection.

Key Performance Highlights

• 99.9% accuracy rate powered by advanced generative AI, deep neural networks, and reinforcement learning
• 10x faster screening compared to traditional approaches, covering molecular docking through FEP-based binding energy predictions
• 85% reduction in time from initial design to validated candidates
• Cuts pre-clinical discovery time by 3x, reduces costs by 15x, and lowers failure risk by 25%

Applications

• Novel Molecule Design: Create unique, active compounds tailored to specific therapeutic targets.
• Target Identification: Rapidly assess target-drug interactions and optimize lead candidates.
• Clinical Success Optimization: Ensure drug candidates meet critical safety and efficacy parameters required to advance into clinical trials.
• Drug Repurposing: Discover alternative therapeutic uses for existing compounds using AI and predictive analytics.

Workflow Steps

1. Input: Begin with a target protein structure or specific pharmacological property requirement.
2. De Novo Design: Generate novel molecules using Medvolt's fragment library and generative AI.
3. Optimization: Refine molecular structures for safety, efficacy, and drug-likeness using reinforcement learning.
4. Screening and Validation: Conduct molecular docking, ADME profiling, and FEP calculations to identify top candidates.
5. Optimized Molecules: Receive a curated library of optimized, validated molecules ready for preclinical testing.

MedGraph - Topaaz™ supports both cloud and on-premise deployment through a cloud-native, infrastructure-agnostic architecture, ensuring adaptability to any research environment. Medvolt's platform is backed by proprietary high-throughput datasets and NLP solutions, and the company collaborates globally with leading pharma and biotech organizations to deliver scalable, impactful drug discovery outcomes.